Clindamycin Fresenius 600 Mg/4 Ml 600 mg/4 ml Solution for injection.
PDF Leaflet Revision Date: 17 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of infections caused by susceptible strains of bacteria.
Dosage (summary)
Adults: 600-2700 mg/day in divided doses; Children: 15-40 mg/kg/day.
Special Populations
- Renal impairment
- Hepatic impairment
- Neonates
Pregnancy & Breastfeeding
Safety in pregnancy not established; crosses into breast milk.
Key Drug Interactions
- Erythromycin
- Vitamin K antagonists
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to clindamycin
- Gastrointestinal disease
- Meningitis
Common side effects
- Pseudomembranous colitis
- Skin rashes
- Diarrhoea
Counselling Points
- Monitor for diarrhoea
- Avoid concurrent use with erythromycin
- Consider alternative in pregnancy
Serious warnings
- Risk of severe colitis
- Gasping syndrome in neonates
- Hypersensitivity reactions
Important Disclaimer
The Clindamycin Fresenius 600 Mg/4 Ml 600 mg/4 ml Solution for injection. professional information leaflet below is the property of Fresenius Kabi Manufacturing Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
